姑息性肿瘤手术治疗无法治愈的头颈癌:适应症和结果:回顾性病例回顾

IF 1.9 Q2 MEDICINE, GENERAL & INTERNAL Precision and Future Medicine Pub Date : 2022-06-30 DOI:10.23838/pfm.2022.00037
Y. S. Cho, Eunkyu Lee, Hokyung Jin, D. Oh, Han-Sin Jeong
{"title":"姑息性肿瘤手术治疗无法治愈的头颈癌:适应症和结果:回顾性病例回顾","authors":"Y. S. Cho, Eunkyu Lee, Hokyung Jin, D. Oh, Han-Sin Jeong","doi":"10.23838/pfm.2022.00037","DOIUrl":null,"url":null,"abstract":"Purpose: Despite the promising palliative effects of radiation treatment, few reports have studied the role of palliative tumor surgery (PTS) in patients with unresectable head and neck cancer (HNC). Thus, we aimed to present the outcomes of PTS in HNC, and suggest a possible surgical indication for PTS.Methods: We retrospectively reviewed the medical records of 18 patients who underwent PTS for HNC between 2002 and 2017. PTS was defined as surgical debulking of tumor or surgery of loco-regionaltumors in patients with distant metastasis. As functional outcomes, we evaluated changes in pain, diet, respiration, and wound care before and after PTS.Results: Squamous cell carcinoma was the common cancer type (72.2%), followed by salivary gland cancers and others. The median overall survival time was 17 months (95% confidence interval, 7.3 to 26.7). PTS significantly reduced the pain score (P= 0.013), and improved cancer-related wounds (P=0.003 in wound infection). Oral swallowing and respiration status did not change after PTS. The recurrenttumor atthe operation bed was clinically detected at post-operative 1 to 2 months with intact skin (without wound problems). Of note, further chemotherapy or other additional cancer treatments was possible in 66.7% of patients with PTS (P=0.002).Conclusion: PTS could provide a meaningful benefitto selected patients with incurable HNC, in terms of pain control and cancer wound management. Thus, PTS is a considerable option for selected HNC patients, based on the accurate evaluation oftumor extent along with multi-disciplinary consultation as well as patient counseling.","PeriodicalId":42462,"journal":{"name":"Precision and Future Medicine","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Palliative tumor surgery for incurable head and neck cancer: indications and outcomes: A retrospective case review\",\"authors\":\"Y. S. Cho, Eunkyu Lee, Hokyung Jin, D. Oh, Han-Sin Jeong\",\"doi\":\"10.23838/pfm.2022.00037\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: Despite the promising palliative effects of radiation treatment, few reports have studied the role of palliative tumor surgery (PTS) in patients with unresectable head and neck cancer (HNC). Thus, we aimed to present the outcomes of PTS in HNC, and suggest a possible surgical indication for PTS.Methods: We retrospectively reviewed the medical records of 18 patients who underwent PTS for HNC between 2002 and 2017. PTS was defined as surgical debulking of tumor or surgery of loco-regionaltumors in patients with distant metastasis. As functional outcomes, we evaluated changes in pain, diet, respiration, and wound care before and after PTS.Results: Squamous cell carcinoma was the common cancer type (72.2%), followed by salivary gland cancers and others. The median overall survival time was 17 months (95% confidence interval, 7.3 to 26.7). PTS significantly reduced the pain score (P= 0.013), and improved cancer-related wounds (P=0.003 in wound infection). Oral swallowing and respiration status did not change after PTS. The recurrenttumor atthe operation bed was clinically detected at post-operative 1 to 2 months with intact skin (without wound problems). Of note, further chemotherapy or other additional cancer treatments was possible in 66.7% of patients with PTS (P=0.002).Conclusion: PTS could provide a meaningful benefitto selected patients with incurable HNC, in terms of pain control and cancer wound management. Thus, PTS is a considerable option for selected HNC patients, based on the accurate evaluation oftumor extent along with multi-disciplinary consultation as well as patient counseling.\",\"PeriodicalId\":42462,\"journal\":{\"name\":\"Precision and Future Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2022-06-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Precision and Future Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.23838/pfm.2022.00037\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Precision and Future Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23838/pfm.2022.00037","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

目的:尽管放射治疗具有很好的姑息效果,但很少有报道研究姑息性肿瘤手术(PTS)在不可切除的癌症(HNC)患者中的作用。因此,我们旨在介绍PTS在HNC中的结果,并提出PTS的可能手术指征。方法:我们回顾性回顾了2002年至2017年间18名因HNC接受PTS的患者的医疗记录。PTS被定义为对远处转移患者进行肿瘤的手术切除或局部区域肿瘤的手术。作为功能结果,我们评估了PTS前后疼痛、饮食、呼吸和伤口护理的变化。结果:鳞状细胞癌是常见的癌症类型(72.2%),其次是唾液腺癌和其他癌症。中位总生存时间为17个月(95%置信区间,7.3至26.7)。PTS显著降低疼痛评分(P=0.013),改善癌症相关伤口(伤口感染P=0.003)。PTS后口腔吞咽和呼吸状态没有变化。手术床上的复发肿瘤在术后1至2个月临床上被发现,皮肤完好无损(没有伤口问题)。值得注意的是,66.7%的PTS患者可以进行进一步的化疗或其他额外的癌症治疗(P=0.002)。因此,基于对肿瘤程度的准确评估以及多学科咨询和患者咨询,PTS对于选定的HNC患者来说是一个相当大的选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Palliative tumor surgery for incurable head and neck cancer: indications and outcomes: A retrospective case review
Purpose: Despite the promising palliative effects of radiation treatment, few reports have studied the role of palliative tumor surgery (PTS) in patients with unresectable head and neck cancer (HNC). Thus, we aimed to present the outcomes of PTS in HNC, and suggest a possible surgical indication for PTS.Methods: We retrospectively reviewed the medical records of 18 patients who underwent PTS for HNC between 2002 and 2017. PTS was defined as surgical debulking of tumor or surgery of loco-regionaltumors in patients with distant metastasis. As functional outcomes, we evaluated changes in pain, diet, respiration, and wound care before and after PTS.Results: Squamous cell carcinoma was the common cancer type (72.2%), followed by salivary gland cancers and others. The median overall survival time was 17 months (95% confidence interval, 7.3 to 26.7). PTS significantly reduced the pain score (P= 0.013), and improved cancer-related wounds (P=0.003 in wound infection). Oral swallowing and respiration status did not change after PTS. The recurrenttumor atthe operation bed was clinically detected at post-operative 1 to 2 months with intact skin (without wound problems). Of note, further chemotherapy or other additional cancer treatments was possible in 66.7% of patients with PTS (P=0.002).Conclusion: PTS could provide a meaningful benefitto selected patients with incurable HNC, in terms of pain control and cancer wound management. Thus, PTS is a considerable option for selected HNC patients, based on the accurate evaluation oftumor extent along with multi-disciplinary consultation as well as patient counseling.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Precision and Future Medicine
Precision and Future Medicine MEDICINE, GENERAL & INTERNAL-
自引率
0.00%
发文量
15
审稿时长
10 weeks
期刊最新文献
Survival rate and death risk for associated pulmonary arterial hypertension: A retrospective population-based study Understanding hikikomori syndrome in clinical settings: a case series Development of colistin resistance via heteroresistance modeling in Klebsiella pneumoniae: A diagnostic study Paraneoplastic neurological syndrome associated with onconeural autoantibodies: report of two cases Durable response to first-line treatment with AZD3759 (zorifertinib) in a patient with epithelial growth factor receptor mutated non-small cell lung cancer and untreated multiple brain metastasis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1